SYS6010 plus enlonstobart for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a type of head and neck cancer called squamous cell carcinoma that has come back or spread and cannot be removed by surgery or treated with chemo and radiation together.
- For the combination group, you must not have had any prior systemic anti-cancer treatment, OR if you had chemo or targeted therapy after surgery, your cancer must have come back at least 6 months after your last dose.
- You must have at least one tumor that can be measured on a CT or MRI scan.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You must not have untreated or active brain metastases, certain other cancers within the past 3 years, or active autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
This study tests a combination of three drugs for people with head and neck cancer that has come back or spread. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a new targeted drug (SYS6010) compared with standard single-drug treatments for advanced head and neck cancer that has not responded to previous therapies. The goal is to see if this new drug can shrink tumors or slow cancer growth better than the usual options.
This trial tests a combination of targeted immunotherapy and chemotherapy given before surgery or radiation for head and neck cancer. The goal is to shrink the tumor and potentially improve outcomes.
This trial tests a new combination of treatments for head and neck cancer that has returned or spread and can't be cured with local therapy. It compares a standard chemotherapy with or without an additional drug to see which is more effective and safe.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.